Subject
Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry
Reference22 articles.
1. M. Imran, M. Kumar Arora, S.M.B. Asdaq, S.A. Khan, S.I. Alaqel, M.K. Alshammari, M.M. Alshehri, A.S. Alshrari, A. Mateq Ali, A.M. Al-Shammeri, B.D. Alhazmi, A.A. Harshan, M.T. Alam, Abida, Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19, Molecules 26 (2021).
2. A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers;Morsy;J. Pharm. Biomed. Anal.,2021
3. A novel, rapid and simple UPLC-MS/MS method for quantification of favipiravir in human plasma: Application to a bioequivalence study;Rezk;Biomedical chromatography : BMC,2021
4. EMA Assessment report, Use of molnupiravir for the treatment of COVID-19, EMA/719664/2021 Corr. 1, Committee for Medicinal Products for Human Use (CHMP), 2021.
5. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2;Painter;Antimicrob. Agents Chemother.,2021
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献